Clinical Trial Goal
To find out:
- The highest dose of INCB160058 that's safe to give
- If INCB160058 is safe and works well to treat myelofibrosis that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have one of the following diseases that has relapsed or is refractory:
- Post-essential thrombocythemia myelofibrosis
- Post-polycythemia vera myelofibrosis
- Primary myelofibrosis
- Have cancer cells of mutation JAK2V617F (JAK2V617F+)
- Have taken 1 JAK inhibitor for at least 3 months and not seen improvement. Your doctor can tell you this
- Have not had an allogeneic (cells from a donor) or autologous (your own cells) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
INCB160058 is a small molecule inhibitor that targets JAK2V617F in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- INCB160058 – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to about 2 years.
The Food and Drug Administration (FDA) has not yet approved INCB160058.
Contacts
Incyte Corporation Call Center (US), 1.855.463.3463, medinfo@incyte.com
Incyte Corporation Call Center (ex-US), +800 00027423, eumedinfo@incyte.com
Locations
Sponsors
lead: Incyte Corporation
